CVS Health Co. (NYSE:CVS) Shares Sold by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. trimmed its position in CVS Health Co. (NYSE:CVS) by 2.8% during the 4th quarter, HoldingsChannel.com reports. The firm owned 435,871 shares of the pharmacy operator’s stock after selling 12,452 shares during the period. Oppenheimer Asset Management Inc.’s holdings in CVS Health were worth $19,566,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. AMF Tjanstepension AB increased its stake in CVS Health by 124.1% during the 3rd quarter. AMF Tjanstepension AB now owns 61,744 shares of the pharmacy operator’s stock worth $3,882,000 after buying an additional 34,198 shares during the period. Pallas Capital Advisors LLC increased its stake in CVS Health by 82.6% during the 3rd quarter. Pallas Capital Advisors LLC now owns 13,616 shares of the pharmacy operator’s stock worth $856,000 after buying an additional 6,158 shares during the period. Integrated Advisors Network LLC increased its stake in CVS Health by 0.7% during the 3rd quarter. Integrated Advisors Network LLC now owns 27,625 shares of the pharmacy operator’s stock worth $1,737,000 after buying an additional 200 shares during the period. Diversify Advisory Services LLC increased its stake in CVS Health by 6.8% during the 3rd quarter. Diversify Advisory Services LLC now owns 28,301 shares of the pharmacy operator’s stock worth $1,780,000 after buying an additional 1,800 shares during the period. Finally, MONECO Advisors LLC increased its stake in CVS Health by 3.6% during the 3rd quarter. MONECO Advisors LLC now owns 19,528 shares of the pharmacy operator’s stock worth $1,228,000 after buying an additional 670 shares during the period. 80.66% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at CVS Health

In other news, Director Michael F. Mahoney purchased 30,000 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were bought at an average cost of $66.70 per share, with a total value of $2,001,000.00. Following the purchase, the director now directly owns 39,356 shares of the company’s stock, valued at approximately $2,625,045.20. This trade represents a 320.65 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.24% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of brokerages have commented on CVS. StockNews.com raised shares of CVS Health from a “sell” rating to a “hold” rating in a research report on Thursday, February 13th. JPMorgan Chase & Co. upped their target price on shares of CVS Health from $80.00 to $81.00 and gave the company an “overweight” rating in a report on Tuesday, February 18th. Deutsche Bank Aktiengesellschaft upgraded shares of CVS Health from a “hold” rating to a “buy” rating and set a $66.00 target price for the company in a report on Tuesday, December 3rd. Royal Bank of Canada lowered their target price on shares of CVS Health from $68.00 to $58.00 and set an “outperform” rating for the company in a report on Friday, November 15th. Finally, Cantor Fitzgerald upgraded shares of CVS Health from a “neutral” rating to an “overweight” rating in a report on Wednesday, February 12th. Four analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, CVS Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $70.00.

CVS Health Stock Performance

Shares of CVS opened at $63.78 on Thursday. The company has a 50-day simple moving average of $53.48 and a 200-day simple moving average of $56.34. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80. The company has a market capitalization of $80.42 billion, a PE ratio of 17.43, a P/E/G ratio of 0.98 and a beta of 0.61. CVS Health Co. has a 52-week low of $43.56 and a 52-week high of $80.75.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.89 by $0.30. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. Equities research analysts predict that CVS Health Co. will post 5.89 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, February 3rd. Shareholders of record on Thursday, January 23rd were issued a dividend of $0.665 per share. The ex-dividend date was Thursday, January 23rd. This represents a $2.66 annualized dividend and a yield of 4.17%. CVS Health’s dividend payout ratio (DPR) is currently 72.68%.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.